Is REMEVi better than MEDVi?

REMEVi offers bilingual English/Spanish support, all-inclusive pricing from $169/month, real human care coordinators with a 2-hour response guarantee, full women's health services, and a clean data security record. MEDVi received an FDA warning letter in 2026, their clinical partner OpenLoop Health suffered a 1.6 million patient data breach, and MEDVi carries an F BBB rating with 361 complaints. The right choice depends on your priorities.

What is the difference between REMEVi and MEDVi pricing?

REMEVi GLP-1 semaglutide starts at $169/month intro then $279/month ongoing, all-inclusive. MEDVi starts at $179/month then $299/month. Both are all-inclusive with no separate membership fees. REMEVi is slightly cheaper and includes bilingual support at no extra cost.

Did MEDVi have a data breach?

Yes. In January 2026, OpenLoop Health — MEDVi's clinical infrastructure partner — confirmed a data breach affecting approximately 1.6 million patient records. The breach was confirmed by the Texas Attorney General's office in March 2026. MEDVi patient data was part of the breach because OpenLoop powers MEDVi's clinical backend.

Does MEDVi have Spanish language support?

MEDVi's platform is primarily English. Some reviewers have noted that visit recaps appear in both English and Spanish, but full bilingual support across all patient touchpoints is not available. REMEVi is the first GLP-1 telehealth platform built bilingual-first, with English and Spanish available at every step.

What is MEDVi's BBB rating?

MEDVi has an F rating with the Better Business Bureau as of 2026, with 361 filed complaints. Common complaint categories include billing issues, unexpected charges after cancellation, difficulty reaching customer support, and refund denials.

REMEVi vs MEDVi (2026): Full Comparison — Pricing, Safety, Data Breach & Bilingual Support

The MEDVi situation in April 2026

Before any comparison, you need to know what has happened at MEDVi in 2026. These are documented facts from public records, not opinions.

FDA Warning Letter — February 2026

The FDA issued a warning letter to MEDVi for making misleading advertising claims — specifically implying their compounded products contained "the same active ingredient" as FDA-approved drugs like Ozempic and Wegovy. This is a federal violation. Source: FDA.gov and STAT News.

1.6 Million Patient Data Breach — January 2026

OpenLoop Health — the company that powers MEDVi's clinical infrastructure — confirmed a data breach affecting approximately 1.6 million patient records, including names, contact information, dates of birth, and medical information. Confirmed by the Texas Attorney General's office in March 2026.

Federal Class Action Lawsuit (RICO) — November 2025

A federal class action complaint was filed in the US District Court for the District of Delaware alleging MEDVi sold compounded oral tirzepatide with "no demonstrated mechanism of absorption or efficacy" — calling it "modern-day snake oil." The complaint brings RICO claims, consumer protection violations, and common law fraud.

F Rating — Better Business Bureau

MEDVi carries an F rating from the BBB — the lowest possible grade — with 361 filed complaints as of April 2026. Complaints center on billing surprises, charges after cancellation, unresponsive customer support, and refund denials.

Side-by-side comparison

Category	REMEVi	MEDVi
GLP-1 semaglutide price	$169 intro / $279/mo ongoing	$179 intro / $299/mo ongoing
All-inclusive (no hidden fees)	Yes — medication, physician, shipping	Yes — but billing complaints documented
Spanish language support	Full bilingual — every touchpoint	English only (some portal recaps in Spanish)
Women's health	Full program — GLP-1, HRT, hair, skin	Available but limited
Data security	Zero breaches. HIPAA certified.	1.6M patient breach via OpenLoop (Jan 2026)
FDA status	LegitScript certified. Compliant.	FDA warning letter issued Feb 2026
Active lawsuits	None	Federal RICO class action filed Nov 2025
BBB rating	A+ (target at launch)	F rating, 361 complaints
Human phone support	Yes — bilingual, 2-hour response	Chat and email — phone puts users on hold
Cancellation	One-click, instant	Complaints about difficulty cancelling
Before/after photos	Real patients only, consented	Deepfake AI photos reported (Futurism)
Clinical partner	Clean security record	OpenLoop Health — breached Jan 2026
Mobile app	Bilingual app (Phase 2)	Web portal only
Tirzepatide price	$289 intro / $369/mo	Similar range
TRT / Men's health	$109 intro / $149/mo	Available

Pricing: REMEVi vs MEDVi

Both platforms use the same all-inclusive cash-pay model — one monthly price covers physician review, medication, and shipping. No insurance required, no separate membership fees. Here's how they stack up:

Semaglutide injectable: REMEVi $169 intro / $279 ongoing vs MEDVi $179 intro / $299 ongoing
Tirzepatide: REMEVi $289 intro / $369 ongoing vs MEDVi comparable range
Women's health / HRT: REMEVi $89 intro / $129 ongoing — MEDVi limited
Men's health / TRT: REMEVi $109 intro / $149 ongoing — MEDVi available

REMEVi is slightly less expensive across all categories, and includes bilingual support at no additional cost — something MEDVi does not offer.

Data security: The most important difference

This is the category where the gap between REMEVi and MEDVi is widest — and most consequential for patients.

MEDVi uses OpenLoop Health as its clinical infrastructure partner. In January 2026, OpenLoop confirmed that a threat actor had breached their systems and exfiltrated records belonging to approximately 1.6 million patients. The stolen data included names, contact information, dates of birth, and medical information. This was not a small incident. 1.6 million people had their personal health data stolen from the company that powers MEDVi's prescribing and clinical operations.

REMEVi does not use OpenLoop Health. REMEVi has had zero data breaches. Our HIPAA compliance program uses only certified infrastructure, and we display our security certifications prominently because we believe patients have a right to know who is protecting their health information.

Bilingual support: The gap no competitor has closed

There are 65 million Spanish-speaking adults in the United States. The obesity rate among Hispanic adults is among the highest of any demographic group. Less than 10% have ever used a prescription weight loss medication.

MEDVi's platform is English-first. One reviewer noted that consultation recaps appear in both English and Spanish — a small detail, but it illustrates the point: adding Spanish as an afterthought is not the same as building bilingual from the ground up.

REMEVi is the first GLP-1 telehealth platform in the United States built bilingual-first. Every intake form, every support interaction, every medication instruction, every patient portal page is available in English and Spanish. Our care coordinators are bilingual. Our educational content is bilingual. If you or a family member prefers to communicate in Spanish, REMEVi is the only GLP-1 platform built for you.

Customer service: Real humans vs automated systems

The most consistent complaint across MEDVi reviews — on ConsumerAffairs, BBB, Reddit, and Trustpilot — is customer service. Patients describe being charged after cancellation, waiting days for responses, and being unable to reach anyone by phone. One reviewer noted: the phone line puts callers on hold indefinitely when they ask about pharmacy partners.

REMEVi was built with a 2-hour response guarantee and bilingual care coordinators available by phone. This is not a feature — it is the entire service model. A patient who can reach a real human being in their own language within 2 hours of a problem is a patient who stays. A patient who gets an automated response after days of waiting is a patient who cancels and leaves a one-star review.

Who should choose MEDVi

MEDVi is a legitimate platform with over 500,000 patients and generally positive medication outcomes. It may still be appropriate if:

You are already an established MEDVi patient with no billing issues and don't want to switch
You are comfortable with the data breach disclosure and have updated your passwords and monitoring
You only need English language support and are not concerned about the FDA warning or lawsuit

Who should choose REMEVi

REMEVi is the stronger choice if any of the following apply:

You prefer to communicate in Spanish or are researching on behalf of a Spanish-speaking family member
You are concerned about MEDVi's data breach and want a platform with a clean security record
You are a woman who wants a full women's health program (GLP-1, HRT, hair, skin) in one place
You have experienced MEDVi's billing or cancellation issues and want a one-click cancellation guarantee
You want to talk to a real human by phone within 2 hours — not wait days for an automated response
You are starting fresh and want the lowest all-in price with the most transparent terms

Frequently asked questions

The honest answer: it depends on what matters to you. On price, REMEVi is slightly cheaper. On data security, REMEVi has a clean record vs MEDVi's 1.6M patient breach. On bilingual support, REMEVi is the only option. On regulatory status, REMEVi has no FDA warning letters vs MEDVi's 2026 warning. On customer service, REMEVi guarantees 2-hour bilingual response vs MEDVi's documented support issues. For Spanish-speaking patients and patients who have had problems with MEDVi, the differences are significant.

Yes. In January 2026, OpenLoop Health — the company that powers MEDVi's clinical operations — confirmed a data breach affecting approximately 1.6 million patients. The stolen data included names, contact information, dates of birth, and medical information. This was confirmed by the Texas Attorney General's office in March 2026. MEDVi patient data was part of the breach because OpenLoop provides MEDVi's physician network and clinical backend.

MEDVi has an F rating — the lowest possible BBB grade — with 361 filed complaints as of April 2026. The most common complaint categories are billing issues and unexpected charges after cancellation, difficulty reaching customer support, refund denials, and inconsistent medication delivery. REMEVi targets an A+ BBB rating from launch by building easy cancellation and responsive bilingual support into the core platform.

MEDVi's platform is primarily English. Some patient portal content appears in both languages, but full bilingual support across intake, support, and care coordination is not offered. REMEVi is the first GLP-1 telehealth platform built bilingual-first — English and Spanish at every touchpoint, including phone support with bilingual coordinators.

Yes. Cancel your MEDVi subscription (use their chat support channel — that is the most reliable path based on patient reviews), then start a new intake with REMEVi. Your medical history and GLP-1 dosing history can be shared with REMEVi's clinical partner during intake to ensure dosing continuity. Do not stop your medication abruptly — time your switch so your last MEDVi shipment overlaps with your first REMEVi approval.

Ready to make the switch?

Bilingual care. Transparent pricing. Real humans. Starting at $169/month all-inclusive.

Get started with REMEVi →

Disclaimer: This comparison is based on publicly available information, BBB records, FDA public filings, court documents, and customer reviews as of April 2026. REMEVi is not affiliated with MEDVi, OpenLoop Health, or their partners. MEDVi is a trademark of MEDVi LLC. All comparative pricing and claims should be independently verified before making a healthcare decision. This content is for informational purposes only and does not constitute medical advice.

REMEVi vs MEDVi (2026):Full Comparison

Bottom line up front